drugset
drugset / Trial / NCT05702450

Study to Evaluate Pharmacokinetics, Safety and Efficacy of CM310

NCT05702450 ↗

Phase 1 Completed 240 enrolled Keymed Biosciences Co.Ltd
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a single-center, randomized, open study to evaluate the pharmacokinetics, safety and immunogenicity CM310 in healthy subjects.

Timeline

Start
2023-03-22
Primary completion
2023-07-26
Completion
2023-07-26

Drugs

EvaluationDrugModalityDoseRoute
Subject CM310 Monoclonal antibody — Subcutaneous

Indications

No indication recorded.